A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

For more information regarding BMS clinical trial participation, please visitwww.BMSStudyConnect.com Inclusion Criteria:

• Adults with either active or a history of non-valvular atrial fibrillation or flutterwith the planned or existing use of an oral anticoagulant for prophylaxis ofthromboembolism. In addition, subjects must have had an acute coronary syndrome orpercutaneous coronary intervention with a stent within the prior 14 days

• Planned use of antiplatelet agents for at least 1 to 6 months

• Males and Females ≥ 18 years of age

• Women of childbearing potential must have a negative serum or urine pregnancy testwithin 24 hours prior to the start of study drug

Exclusion Criteria:

• Conditions other than atrial fibrillation that require chronic anticoagulation. (e.g.prosthetic mechanical heart valve)

• Severe renal insufficiency (serum creatinine > 2.5 mg/dL or a calculated creatinineclearance < 30 mL/min

• Patients with a history of intracranial hemorrhage

• Patients have had or will undergo Coronary arterial bypass graft (CABG) for theirindex acute coronary syndrome (ACS) event

• Patients with known ongoing bleeding and patients with known coagulopathies

• Any contraindications or allergies to VKA, apixaban, or to intended P2Y12 antagonistsor to aspirin